I-Mab (NASDAQ:BDTX) Major Shareholder Sells $11,687.83 in Stock

I-Mab (NASDAQ:BDTX) major shareholder Versant Venture Capital Vi, L. sold 353 shares of the business’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $33.11, for a total value of $11,687.83. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Versant Venture Capital Vi, L. also recently made the following trade(s):

  • On Wednesday, October 14th, Versant Venture Capital Vi, L. sold 4,859 shares of I-Mab stock. The shares were sold at an average price of $33.09, for a total value of $160,784.31.
  • On Thursday, October 8th, Versant Venture Capital Vi, L. sold 16,276 shares of I-Mab stock. The shares were sold at an average price of $33.47, for a total value of $544,757.72.
  • On Tuesday, October 6th, Versant Venture Capital Vi, L. sold 15,980 shares of I-Mab stock. The shares were sold at an average price of $33.26, for a total value of $531,494.80.
  • On Monday, August 10th, Versant Venture Capital Vi, L. sold 5,492 shares of I-Mab stock. The shares were sold at an average price of $33.04, for a total value of $181,455.68.

Shares of BDTX opened at $33.70 on Friday. The stock has a market capitalization of $1.21 billion and a price-to-earnings ratio of -1.98. I-Mab has a 1 year low of $17.63 and a 1 year high of $46.25. The business’s 50 day simple moving average is $30.20 and its 200-day simple moving average is $33.30.

I-Mab (NASDAQ:BDTX) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.03. As a group, analysts expect that I-Mab will post -2.11 earnings per share for the current year.

A number of research analysts recently commented on the company. Zacks Investment Research raised I-Mab from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a report on Wednesday, August 12th. BidaskClub raised I-Mab from a “strong sell” rating to a “sell” rating in a report on Friday, October 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $53.00 price target on shares of I-Mab in a report on Wednesday, August 12th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $45.60.

I-Mab Company Profile

Black Diamond Therapeutics, Inc, a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase.

Further Reading: How to Use a Moving Average for TradingĀ 

Insider Buying and Selling by Quarter for I-Mab (NASDAQ:BDTX)

Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.